Clinical Endocrinology最新文献

筛选
英文 中文
Diagnostic Options in Graves' or Non-Graves' Thyrotoxicosis: A Review for Clinical Practice 格雷夫斯或非格雷夫斯甲状腺毒症的诊断选择:临床实践综述。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-07-31 DOI: 10.1111/cen.70192
Lorenzo Scappaticcio, Pierpaolo Trimboli, Paola Caruso, Chiara Porcellini, Daniela Forestiere, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella
{"title":"Diagnostic Options in Graves' or Non-Graves' Thyrotoxicosis: A Review for Clinical Practice","authors":"Lorenzo Scappaticcio,&nbsp;Pierpaolo Trimboli,&nbsp;Paola Caruso,&nbsp;Chiara Porcellini,&nbsp;Daniela Forestiere,&nbsp;Maria Ida Maiorino,&nbsp;Katherine Esposito,&nbsp;Giuseppe Bellastella","doi":"10.1111/cen.70192","DOIUrl":"10.1111/cen.70192","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging. We aim to provide clinicians with a practical guide to achieve a more reliable etiological diagnosis of thyrotoxicosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed international guidelines and the main papers indexed in PubMed from inception to March 1, 2026, on the diagnosis of thyrotoxicosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three major diagnostic tools are currently available: thyroid scintigraphy, thyrotropin receptor antibodies (TRAbs), and thyroid ultrasonography (US). The diagnostic accuracy of scintigraphy is approximately 96%. However, GD may also present with non-uniform or normal uptake in 5–12% of cases. The diagnostic accuracy of TRAbs is approximately 95%. Nevertheless, TRAbs have limited utility in three specific settings: TRAb-negative GD, TRAb positivity in non-GD patients, and type 1 amiodarone-induced thyrotoxicosis (AIT). Thyroid US is the third most accurate diagnostic tool, with an accuracy of approximately 77%. Minor diagnostic tools include: T3/T4 and fT3/fT4 ratios; fT3/TSH and fT4/TSH ratios; serum diiodotyrosine; blood cell line ratios; and selected extrathyroidal manifestations of GD, such as neutropenia, abnormal liver function tests, and thymic hyperplasia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>One or more major diagnostic tools may be used to establish the final etiological diagnosis of thyrotoxicosis, depending on test availability, turnaround time, and clinician expertise. Minor diagnostic tools may provide additional diagnostic information in selected or equivocal cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"603-609"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.70192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-Reported Health Burden and Quality-of-Life–Related Concerns in Patients With Achondroplasia: A Survey From Türkiye 软骨发育不全患者自我报告的健康负担和生活质量相关问题:一项来自<s:1> rkiye的调查
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-08-06 DOI: 10.1111/cen.70190
Zehra Aycan, Murat Berge, Sukran Darcan, Saadet Olcay Evliyaoglu, Fatih Suheyl Ezgu, Ercan Mihci, Feristah Ferda Ozkinay
{"title":"Self-Reported Health Burden and Quality-of-Life–Related Concerns in Patients With Achondroplasia: A Survey From Türkiye","authors":"Zehra Aycan,&nbsp;Murat Berge,&nbsp;Sukran Darcan,&nbsp;Saadet Olcay Evliyaoglu,&nbsp;Fatih Suheyl Ezgu,&nbsp;Ercan Mihci,&nbsp;Feristah Ferda Ozkinay","doi":"10.1111/cen.70190","DOIUrl":"10.1111/cen.70190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Achondroplasia is an autosomal dominant genetic disorder, characterised by distinctive growth patterns and recognisable skeletal features. This study aimed to determine the demographic and clinical characteristics, quality of life (QoL) losses, and expectations of individuals with achondroplasia in Türkiye.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>In this survey-based study, Computer-Assisted Telephone Interviewing (CATI) system was used and questions were directed to patients or their parents via phone calls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients</h3>\u0000 \u0000 <p>A total of 140 patients with achondroplasia, of whom 50.7% were male (age range, 0–20 years) were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>The questionnaire forms were prepared by a committee including clinicians and the president of the Achondroplasia and Families Association. The forms included questions on sociodemographic characteristics, diagnosis and treatment, expectations from the patient association, and quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Achondroplasia was commonly diagnosed by obstetricians (76.5%) and the patients were followed by multiple specialties. Of the patients, 10% received growth hormone treatment, and 55.7% underwent at least one surgical procedure, with 23.6% undergoing limb lengthening surgery. The main symptoms frequently/very frequently observed in the patients were: sleep-disordered breathing (40%), recurrent ear infections (32%), and frequent respiratory tract infections (28%). The primary concerns involved experiences of social exclusion due to physical appearance and together with related psychological challenges. The main expectations of the participants and parents from the association were to receive education on achondroplasia management and new treatment options, and to promote public awareness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with achondroplasia face significant challenges in daily life, they require medical treatment and some supportive services to improve their quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"651-659"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Malignancy and False-Negative Risk in Large (≥ 3 cm) Thyroid Nodules: Insights From a Single-Centre Thyroidectomy Cohort 大甲状腺结节(≥3cm)恶性肿瘤和假阴性风险的预测因素:来自单中心甲状腺切除术队列的见解
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-07-29 DOI: 10.1111/cen.70185
Ömer Komaç, Elif Bilgili, Merve Yetişken, Deniz Çetin, Nesibe Kahraman Çetin, Ogün Aydoğan, Göksel Tuzcu, İmran Kurt Ömürlü, Mustafa Ünübol, Mustafa Gökhan Ünsal, Engin Güney
{"title":"Predictors of Malignancy and False-Negative Risk in Large (≥ 3 cm) Thyroid Nodules: Insights From a Single-Centre Thyroidectomy Cohort","authors":"Ömer Komaç,&nbsp;Elif Bilgili,&nbsp;Merve Yetişken,&nbsp;Deniz Çetin,&nbsp;Nesibe Kahraman Çetin,&nbsp;Ogün Aydoğan,&nbsp;Göksel Tuzcu,&nbsp;İmran Kurt Ömürlü,&nbsp;Mustafa Ünübol,&nbsp;Mustafa Gökhan Ünsal,&nbsp;Engin Güney","doi":"10.1111/cen.70185","DOIUrl":"10.1111/cen.70185","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Whether nodule size compromises cytologic reliability remains controversial in managing large thyroid nodules. This study evaluated malignancy prevalence, predictors and false-negative (FN) cytology in a surgical cohort enriched for nodules ≥ 3 cm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 285 thyroidectomy patients (2018–2024) with a ≥ 3 cm dominant nodule. Each patient represented one analytic unit. The study assessed malignancy rates, clinical and imaging predictors, and FN risk among cytologically benign (Bethesda II) nodules. Demographic, biochemical and sonographic data—including nodule size, composition, EU-TIRADS category and suspicious lymphadenopathy (LAP)—were retrieved from records. Multivariable logistic regression with bootstrap validation identified independent predictors of malignancy and factors linked to false negativity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Observed malignancy proportion was 13.3% in this thyroidectomy cohort (38/285), predominantly papillary carcinoma. Independent predictors: EU-TIRADS TR4–5 (OR 7.6) and suspicious LAP (OR 6.0); size ≥ 4 cm (OR 2.6) and solid composition (OR 3.3) exerted smaller effects. Among 111 Bethesda II cases, postoperative malignancy occurred in five (4.5%), all in ≥ 4 cm nodules (7.5% vs. 0%; <i>p</i> = 0.023). Post hoc review of FN cases suggested cystic/infiltrative features potentially contributing to sampling limitations. Nodule size had a moderate association with FN probability (AUC 0.75).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this surgically selected cohort of large thyroid nodules, sonographic risk, suspicious LAP and clinical context outperformed size alone in predicting malignancy. Even with benign cytology, nodules ≥ 4 cm with higher-risk imaging or structural features may warrant repeat or targeted FNAB, core biopsy, or surgery, whereas lower-risk phenotypes may still be considered for surveillance. These findings support a risk-stratified, node-informed approach beyond purely size-driven surgery in surgically referred large nodules, although extrapolation to all large nodules in the general population should be made cautiously.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"667-679"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study” 更正“二甲双胍vs肌醇:肥胖多囊卵巢综合征患者哪个更好?”随机对照交叉研究”。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-09-15 DOI: 10.1111/cen.70207
{"title":"Correction to “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study”","authors":"","doi":"10.1111/cen.70207","DOIUrl":"10.1111/cen.70207","url":null,"abstract":"<p>Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A. and Guido, M. (2017), Metformin <i>vs</i> Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study. Clin Endocrinol, 86: 725–730. https://doi.org/10.1111/cen.13304</p><p>In Table 1:</p><p>The value “29.7 (IQR 7.8)” in the “BMI (kg/m<sup>2</sup>)” row under the “Baseline (IQR)” of “Metformin” was incorrect and should be “32.5 (IQR 7.9)”.</p><p>The value “32.5 (IQR 7.9)” in the “BMI (kg/m<sup>2</sup>)” row under the “After 6 months (IQR)” of “Metformin” was incorrect and should be “29.7 (IQR 7.8)”.</p><p>The value “10.52 (37.78)” in the “Ovarian Volume (cm<sup>3</sup>)” row under the “After 6 months (IQR)” of “MYO” was incorrect and should be “10.52 (3.78)”.</p><p>The value “02.3 (1.1)” in the “17(OH)P (nmol/l)” row under the “After 6 months (IQR)” of “MYO” was incorrect and should be “2.3 (1.1)”.</p><p>The correct Table 1 is provided below.</p><p>We apologize for this error.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"680-681"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.70207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sagliker Syndrome: A Case Series and Literature Review With Clinical Characteristics, Post Parathyroidectomy Biochemical Trajectories and Hungry Bone Syndrome. Sagliker综合征:包括临床特征、甲状旁腺切除术后生化轨迹和饥饿骨综合征的病例系列和文献综述。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-27 DOI: 10.1111/cen.70226
Siddharth Madhad, Puneet Bhardwaj, Amal Shaharyar, Vivek Jha, Soham Mukherjee, Divya Dahiya, Uma Nahar Saikia, Rimesh Pal, Sanjay Kumar Bhadada
{"title":"Sagliker Syndrome: A Case Series and Literature Review With Clinical Characteristics, Post Parathyroidectomy Biochemical Trajectories and Hungry Bone Syndrome.","authors":"Siddharth Madhad, Puneet Bhardwaj, Amal Shaharyar, Vivek Jha, Soham Mukherjee, Divya Dahiya, Uma Nahar Saikia, Rimesh Pal, Sanjay Kumar Bhadada","doi":"10.1111/cen.70226","DOIUrl":"https://doi.org/10.1111/cen.70226","url":null,"abstract":"<p><strong>Objective: </strong>To describe the clinical, biochemical, radiological, histopathological, and postoperative characteristics of patients with Sagliker syndrome.</p><p><strong>Methods: </strong>Three patients with dialysis-dependent end-stage renal disease and Sagliker syndrome who underwent parathyroidectomy at our institution were retrospectively analysed. A literature review identified six published reports with detailed clinical, biochemical, radiological, surgical, and postoperative data suitable for comparative analysis.</p><p><strong>Results: </strong>All three patients presented with progressive diffuse craniofacial skeletal remodelling characterised by maxillomandibular enlargement, facial widening, and severe secondary hyperparathyroidism. Preoperative intact parathyroid hormone concentrations ranged from 2258 to 4750 pg/mL, accompanied by marked hyperphosphatemia and elevated alkaline phosphatase levels consistent with advanced high-turnover bone disease. Sequential clinical imaging demonstrated progression from preserved facial morphology to severe craniofacial deformity following end-stage renal disease. Radiologic findings included osteitis fibrosa cystica, acro-osteolysis, and salt-and-pepper skull appearance. All patients developed severe postoperative hungry bone syndrome requiring intensive calcium and calcitriol supplementation following parathyroidectomy. Published reports demonstrated a highly concordant results with prolonged dialysis exposure, female predominance, severe biochemical hyperparathyroidism, diffuse craniofacial involvement, and frequent postoperative hypocalcemia.</p><p><strong>Conclusions: </strong>Early recognition and optimal management of CKD-MBD is pivotal in preventing severe, irreversible complications, including craniofacial deformities.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Nodular Goiter on the Short-Term Efficacy of Radioactive Iodine Therapy for Differentiated Thyroid Carcinoma: A Propensity Score Matching Study. 结节性甲状腺肿对放射性碘治疗分化型甲状腺癌短期疗效的影响:倾向评分匹配研究。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-27 DOI: 10.1111/cen.70229
Rui Zhu, Yi Wu, Yang-Yang Lei, Zhao-Xia Luo, Ling-Peng Zeng
{"title":"The Impact of Nodular Goiter on the Short-Term Efficacy of Radioactive Iodine Therapy for Differentiated Thyroid Carcinoma: A Propensity Score Matching Study.","authors":"Rui Zhu, Yi Wu, Yang-Yang Lei, Zhao-Xia Luo, Ling-Peng Zeng","doi":"10.1111/cen.70229","DOIUrl":"https://doi.org/10.1111/cen.70229","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether concomitant nodular goiter (NG) affects the short-term efficacy of radioactive iodine (RAI) therapy in postoperative differentiated thyroid carcinoma (DTC) patients.</p><p><strong>Methods: </strong>A total of 1017 DTC patients who received initial RAI therapy between May 2018 and May 2025 were retrospectively enroled and divided into NG (n = 239) and Non-NG (n = 778) groups. Short-term efficacy was defined according to the 2015 American Thyroid Association (ATA) criteria. Univariable and multivariable logistic regression and propensity score matching (PSM) were used to assess the association between NG and short-term efficacy. Sensitivity analyses were repeated in the thyroglobulin antibody (TgAb)-negative subgroup.</p><p><strong>Results: </strong>Before PSM, multivariable analysis showed that NG was associated with lower odds of non-excellent response (NER) (OR = 0.60, 95% CI: 0.41-0.87, p = 0.008). After PSM, 221 matched pairs were obtained and NG was no longer significantly associated with NER (OR = 0.67, 95% CI: 0.42-1.06, p = 0.089), whereas N1b stage (OR = 4.78, 95% CI: 1.50-18.38, p = 0.013) and elevated pretreatment stimulated thyroglobulin (sTg) (OR = 1.10, 95% CI: 1.06-1.14, p < 0.001) were independently associated with NER. Sensitivity analyses in TgAb-negative patients yielded consistent findings. In the overall cohort, the AUC of sTg for predicting NER was 0.814 in the NG group and 0.738 in the Non-NG group (DeLong p = 0.027); this difference was not observed in the TgAb-negative subgroup (0.854 vs. 0.846, p = 0.801).</p><p><strong>Conclusion: </strong>After controlling for measured baseline confounding using PSM, concomitant NG was not an independent factor associated with short-term RAI therapy efficacy in patients with DTC. N1b stage and elevated pretreatment sTg were independently associated with poor short-term response.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline Predictors of Incomplete Biochemical and Radiological Outcomes During Cabergoline Treatment of Prolactinomas: A Retrospective Cohort From a Tertiary Referral Center. 卡麦角林治疗催乳素瘤期间不完全生化和放射预后的基线预测因素:来自三级转诊中心的回顾性队列。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-26 DOI: 10.1111/cen.70223
Manuel Ramón García-Sáenz, Diana Isela Rodríguez-Landeros, Diana Laura Molina-Guerrero, Claudia Ramírez-Rentería, Aldo Ferreira-Hermosillo, Moisés Mercado-Atri, Ernesto Sosa-Eroza, Emilio Fernández Lemmen Meyer, Etual Espinosa-Cárdenas
{"title":"Baseline Predictors of Incomplete Biochemical and Radiological Outcomes During Cabergoline Treatment of Prolactinomas: A Retrospective Cohort From a Tertiary Referral Center.","authors":"Manuel Ramón García-Sáenz, Diana Isela Rodríguez-Landeros, Diana Laura Molina-Guerrero, Claudia Ramírez-Rentería, Aldo Ferreira-Hermosillo, Moisés Mercado-Atri, Ernesto Sosa-Eroza, Emilio Fernández Lemmen Meyer, Etual Espinosa-Cárdenas","doi":"10.1111/cen.70223","DOIUrl":"https://doi.org/10.1111/cen.70223","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Although cabergoline is the treatment of choice for prolactinomas, a non-negligible proportion of patients show incomplete biochemical and/or tumoral response. Although several baseline factors have been associated with dopamine agonist resistance, their predictive value remains inconsistent. We aimed to evaluate whether baseline clinical, biochemical, and gross tumor burden variables are associated with incomplete biochemical and radiological response to cabergoline in prolactinomas using a predefined composite operational outcome.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a retrospective observational cohort study at a tertiary care center in Mexico City. Adult patients with prolactinomas treated with cabergoline were included. The primary outcome was incomplete response to cabergoline, defined using a predefined operational composite endpoint requiring both prolactin normalization and at least 30% estimated tumor volume reduction during follow-up. Follow-up duration and cabergoline dose exposure were summarized descriptively and component analyses evaluated biochemical and radiological response separately. A sensitivity analysis used at least 30% tumor diameter reduction instead of volume reduction. Baseline characteristics were compared between responders and patients with incomplete response. Multivariable models including only baseline variables were constructed to identify independent baseline factors associated with incomplete response. Because maximal tolerated cabergoline dose and the reasons for dose non-escalation were not uniformly available, this endpoint was used exclusively as a research classification; non-attainment was not interpreted as clinical treatment failure or dopamine-agonist resistance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 226 patients were included. Using the primary volume-based definition, 140 patients (61.9%) were classified as responders and 86 (38.1%) as having incomplete response. Follow-up duration from cabergoline initiation to the last clinical assessment was calculable in 225 patients, with a median duration of 107 months (IQR 56.5-153.5). The median cabergoline dose at 12 months was 1.5 mg/week (IQR 1.0-2.0), and 61 patients (27.0%) had received ≥ 2 mg/week at that time. In unadjusted analyses, age, sex, baseline estimated tumor volume, and tumor size category were not associated with incomplete response, whereas baseline prolactin showed only a weak non-significant trend. In the primary multivariable model, none of the baseline variables independently identified patients with incomplete response. In exploratory component analyses, 140 patients (61.9%) achieved both prolactin normalization and ≥ 30% estimated tumor volume reduction, 14 (6.2%) achieved prolactin normalization only, 46 (20.4%) achieved ≥ 30% estimated tumor volume reduction only, and 26 (11.5%) achieved neither endpoint. Higher baseline prolactin was associated with incomplete biochemical response (adjust","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor in Response to Comment on "ACTH Stimulation Testing Is Often Unnecessary After Appropriate Patient Preparation Prior to Screening Cortisol Measurement" by Malik M. M. 马利克·M·M·对“在筛选皮质醇测量之前进行适当的患者准备后,ACTH刺激试验通常是不必要的”评论的回复编辑的信。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-20 DOI: 10.1111/cen.70227
Christopher J Symonds, Alexander A Leung, Gregory A Kline
{"title":"Letter to the Editor in Response to Comment on \"ACTH Stimulation Testing Is Often Unnecessary After Appropriate Patient Preparation Prior to Screening Cortisol Measurement\" by Malik M. M.","authors":"Christopher J Symonds, Alexander A Leung, Gregory A Kline","doi":"10.1111/cen.70227","DOIUrl":"https://doi.org/10.1111/cen.70227","url":null,"abstract":"","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149230930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Ultrasound-Guided Ethanol Ablation for Benign Insulinoma: A Single-Centre Experience and Literature Review. 超声内镜下乙醇消融治疗良性胰岛素瘤:单中心经验及文献回顾。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-14 DOI: 10.1111/cen.70219
Yuchao Wu, Haitao Shi, Xiaokang Wu, Ying Kong, Xueqian Li, Lijing Yan, Juanjuan Wu, Shimei Ding, Jing Zhang, Ruo Zhang, Chunhong Zhang, Jing Xu, Aiyu Jing, Xuan Xie, Shiyang Ma, Yang Jiao
{"title":"Endoscopic Ultrasound-Guided Ethanol Ablation for Benign Insulinoma: A Single-Centre Experience and Literature Review.","authors":"Yuchao Wu, Haitao Shi, Xiaokang Wu, Ying Kong, Xueqian Li, Lijing Yan, Juanjuan Wu, Shimei Ding, Jing Zhang, Ruo Zhang, Chunhong Zhang, Jing Xu, Aiyu Jing, Xuan Xie, Shiyang Ma, Yang Jiao","doi":"10.1111/cen.70219","DOIUrl":"https://doi.org/10.1111/cen.70219","url":null,"abstract":"<p><strong>Objectives: </strong>Insulinoma is a predominantly benign pancreatic neuroendocrine tumour that is traditionally managed surgically. However, surgical invasiveness and anaesthesia-related risks limit its applicability in selected patients. Endoscopic ultrasound (EUS)-guided ethanol ablation has emerged as a minimally invasive alternative. This study aimed to evaluate the efficacy, safety, and feasibility of EUS-guided ethanol ablation for benign insulinoma.</p><p><strong>Methods: </strong>We retrospectively analysed 17 patients with insulinoma who underwent EUS-guided ethanol ablation, predominantly as a primary treatment. All procedures were performed by experienced gastroenterologists using 95% absolute ethanol.</p><p><strong>Results: </strong>The study cohort had a mean age of 58.47 ± 12.29 years and a mean disease duration of 34.43 months (range, 0.36-84.0). Clinical success was achieved in 16 patients (94.1%). One patient with an initial suboptimal response successfully underwent a repeat ablation after 8 months. Over a median follow-up period of 46.1 months (range, 6.6-97.8), one patient was lost to follow-up. Disease recurrence was observed in four patients, resulting in a recurrence rate of 25% (4/16) among those with available follow-up data. Three recurrent cases underwent repeat ablation, all achieving symptomatic resolution. A total of 22 ablation procedures were performed. Adverse events were documented in 36.4% (8/22) of procedures, with the majority being mild (31.8%, 7/22) and one severe adverse event (4.5%, 1/22).</p><p><strong>Conclusions: </strong>EUS-guided ethanol ablation is an effective and well-tolerated treatment for benign insulinoma. It represents a viable minimally invasive alternative to surgery and remains effective for managing recurrence or initial treatment failure without compromising subsequent surgical options.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LGALS3 Drives Dopamine Agonist Resistance in Prolactinoma by Activating the MAPK/ERK Pathway: A Multi-Omics Study. LGALS3通过激活MAPK/ERK通路驱动催乳素瘤中多巴胺激动剂的耐药性:一项多组学研究
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-10-14 DOI: 10.1111/cen.70220
Changjun Rao, Xiaoyan Liu, Yangyu Luo, Chuzhong Li, Zerui Wu
{"title":"LGALS3 Drives Dopamine Agonist Resistance in Prolactinoma by Activating the MAPK/ERK Pathway: A Multi-Omics Study.","authors":"Changjun Rao, Xiaoyan Liu, Yangyu Luo, Chuzhong Li, Zerui Wu","doi":"10.1111/cen.70220","DOIUrl":"https://doi.org/10.1111/cen.70220","url":null,"abstract":"<p><strong>Background: </strong>Dopamine agonist resistance is observed in 10%-30% of patients with prolactinomas, resulting in therapeutic failure and tumour progression. The molecular mechanisms underlying this resistance are not yet fully understood, highlighting the need for the identification of novel biomarkers and therapeutic targets.</p><p><strong>Methods: </strong>We performed a comprehensive integrative analysis of bulk RNA sequencing and single-cell RNA sequencing datasets obtained from dopamine agonist-resistant and dopamine agonist-sensitive prolactinomas. To substantiate the primary findings, we utilised a multifaceted methodological framework that integrated Weighted Gene Co-expression Network Analysis with machine learning techniques, including Random Forest, Support Vector Machine, and Least Absolute Shrinkage and Selection Operator. This was complemented by functional assays, which encompassed in vitro experiments involving gene overexpression and knockdown in GH3 cell models, alongside in vivo investigations using nude mouse xenograft models.</p><p><strong>Results: </strong>LGALS3 has been identified as a pivotal factor in mediating resistance. Through single-cell RNA sequencing analysis, a resistance-specific subpopulation, termed Cluster 15, was discovered. This cluster is characterised by heightened genomic instability and stemness, as evidenced by increased expression of SOX2 and SOX9, with predominant expression of LGALS3. Mechanistically, LGALS3 activates the MAPK/ERK signalling pathway, which in turn enhances cell viability, prolactin secretion, and migration, while simultaneously inhibiting apoptosis by modulating the Bax/Bcl-2/Caspase cascade. Functional validation studies demonstrated that silencing LGALS3 significantly reduced tumour growth both in vitro, as shown by decreased Ki67 proliferation and impaired migration, and in vivo, as indicated by reduced tumour weight and volume.</p><p><strong>Conclusion: </strong>LGALS3 functions as a candidate diagnostic biomarker and represents a promising therapeutic target. Targeting the LGALS3-MAPK axis presents a viable strategy to restore therapeutic sensitivity in patients with refractory prolactinoma.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书